HC Wainwright Issues Pessimistic Forecast for TRAX Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS forecast for First Tracks Biotherapeutics to a loss of $0.96 per share from a prior estimate of $0.90, while maintaining a Buy rating and a $57 price target.
• TRAX reported a quarterly loss of $0.95 per share, missing analysts’ consensus estimate of a $0.74 loss by $0.21.
• Despite the earnings miss, analyst sentiment remains favorable: the stock has a consensus “Moderate Buy” rating and an average price target of $60.50, with several firms recently raising their targets.

First Tracks Biotherapeutics (NASDAQ:TRAX - Free Report) - Investment analysts at HC Wainwright lowered their Q3 2026 EPS estimates for shares of First Tracks Biotherapeutics in a research note issued on Thursday, August 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.96) per share for the quarter, down from their prior forecast of ($0.90). HC Wainwright has a "Buy" rating and a $57.00 price objective on the stock. The consensus estimate for First Tracks Biotherapeutics' current full-year earnings is ($4.02) per share. HC Wainwright also issued estimates for First Tracks Biotherapeutics' Q4 2026 earnings at ($1.00) EPS, FY2026 earnings at ($4.35) EPS, FY2027 earnings at ($3.83) EPS, FY2028 earnings at ($3.84) EPS, FY2029 earnings at ($2.80) EPS and FY2030 earnings at ($2.17) EPS.

Several other analysts have also weighed in on TRAX. Wedbush lifted their target price on shares of First Tracks Biotherapeutics from $60.00 to $70.00 and gave the company an "outperform" rating in a research report on Thursday. Zacks Research upgraded shares of First Tracks Biotherapeutics to a "hold" rating in a research report on Monday, April 27th. Piper Sandler upped their price objective on shares of First Tracks Biotherapeutics from $54.00 to $95.00 and gave the stock an "overweight" rating in a research note on Thursday. UBS Group raised their price objective on shares of First Tracks Biotherapeutics from $45.00 to $65.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Finally, Leerink Partners started coverage on First Tracks Biotherapeutics in a report on Friday, April 24th. They issued an "outperform" rating and a $46.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $60.50.

First Tracks Biotherapeutics Price Performance

Shares of NASDAQ:TRAX opened at $44.04 on Monday. The firm has a market cap of $1.57 billion and a price-to-earnings ratio of -23.93. First Tracks Biotherapeutics has a 1-year low of $14.72 and a 1-year high of $49.91. The stock's 50 day moving average price is $30.39.

First Tracks Biotherapeutics (NASDAQ:TRAX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.21).

About First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source